Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Richard Dean Braatz · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2021 · $500,000 — Project Summary: A modular platform for rapid VLP vaccine development and manufacturing for SARS-CoV-2 pandemic response This proposal aims to design, develop, and manufacture a virus-like particle (VLP) vaccine for SARS-CoV-2, and the techniques developed throughout the work can be applied to accel…
Zhenyu Zhong · UT SOUTHWESTERN MEDICAL CENTER · 2021 · $410,000 — Project Summary A balanced supply of deoxynucleoside triphosphates (dNTPs), the building blocks for DNA, is vital for the synthesis or repair of both nuclear and mitochondrial genomes, whereas its imbalance results in genome instability that precipitates cellular damage and breach of homeostasis. Re…
Jonathan Kyle Pokorski · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2021 · $237,000 — Summary The rapid development, distribution and administration of a COVID-19 vaccine to the global population is the most effective approach to quell this pandemic and future reoccurrence. Vaccination must occur broadly both in well-resourced and resource-poor areas of the world to be most effective…
David R Tabatadze · ZATA PHARMACEUTICALS, INC. · 2021 · $717,598 — ABSTRACT Presently, convalescent plasma (CP) transfusion is being developed as a therapy for COVID-19 patients and as a prophylactic for high risk individuals. In addition, treatment with plasma or neutralizing antibody preparations from convalescent patients could be the only treatment for emergin…
JEFFREY K ACTOR · 7 HILLS PHARMA, LLC · 2021 · $297,724 — Abstract On March 11, 2020 the World Health Organization (WHO) announced a global Coronavirus Disease 2019 (COVID-19) pandemic. The disease is characterized by severe flu-like symptoms, with advanced age (>65 years) an important risk factor for SARS-CoV-2-induced death. Current clinical stage CoV-2 …
Rama Rao Amara · EMORY UNIVERSITY · 2021 · $187,664 — The overall goal of this proposal is to develop effective prophylactic vaccines against the novel SARS Coronavirus-2 (SARS-CoV-2) infection that has recently emerged as a pandemic across the world. The SARS-CoV-2 has already infected more than 120,000 people and over 4000 people died due to COVID-19…
Eva Harris · UNIVERSITY OF CALIFORNIA BERKELEY · 2021 · $207,743 — Supplement to R21: Mechanism and in vivo activity of novel glycan-based therapy against flavivirus endothelial permeability and vascular leak Evaluation of therapeutics targeting SARS-CoV-2 infection and defining pathogenic mechanisms of SARS-CoV-2-triggered pulmonary dysfunction Abstract The emergi…
Galit Alter · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $355,594 — Since 2002, several coronaviruses have emerged able to cause severe respiratory disease, however no vaccine is available to prevent these rapidly spreading pathogens. Vaccine design has specifically lagged due to our lack of understanding of the correlates of immunity against these pathogens. Both c…
STEVEN E REIS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2021 · $976,487 — ABSTRACT The pandemic prompted by the novel SARS-COV-2 virus continues to have a devastating effect on the physical, social, and economic health of communities throughout the world. To evaluate the sero-prevalence of immunity against SARS-COV-2 in the United States, this scientific partnership of Cl…
Ya-Wen Chen · UNIVERSITY OF SOUTHERN CALIFORNIA · 2021 · $421,219 — Project Summary In December of 2019, a novel coronavirus, now referred to as severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), struck Wuhan, China and unleashed the current coronavirus disease (COVID-19) pandemic. There are currently no medications or vaccines proven to be effective fo…
JULIE M. OVERBAUGH · FRED HUTCHINSON CANCER RESEARCH CENTER · 2021 · $489,662 — The ongoing global pandemic of the novel SARS-CoV-2 coronavirus (CoV) presents an urgent need for development of effective preventative and treatment therapies. The viral-host cell fusion (S) protein spike is a prime target for such therapies owing to its critical role in the virus lifecycle. The S …
Lovick Edward Cannon · NOVAB, INC. · 2021 · $256,506 — PROJECT SUMMARY There is an urgent need to rapidly detect SARS-CoV-2 (CoV-2) virus in clinical and nonclinical settings, including point of care sites, workplace, and home, at sensitivity and specificity comparable or superior to RT-PCR detection of CoV-2 RNA. Much of the person-to-person CoV-2 tran…
JAMES Jeiwen CHOU · BOSTON CHILDREN'S HOSPITAL · 2021 · $834,248 — Project Summary The first critical step for enveloped viruses, such as HIV-1, to enter host cells is viral membrane fusion. Viral fusion proteins are fascinating protein folding machineries capable of adopting completely different conformations during the fusion process; they are also important vac…
Helen E Scharfman · NATHAN S. KLINE INSTITUTE FOR PSYCH RES · 2021 · $404,250 — ABSTRACT It has been suggested that neuronal hyperexcitability is an important characteristic in Alzheimer’s disease (AD) because it contributes to the impairment in memory and increasing levels of amyloid β (Aβ) that characterize the disease. Using animal models of AD neuropathology we suggest tha…
Bernard Moss · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $1,846,692 — There are many diseases for which there are no vaccines and others for which the vaccines are not optimal or have significant side effects. The objectives of this project are to develop new vectors, characterize viral antigens, determine targets of humoral and cell mediated immunity, and use this i…
PETER D. SUN · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $158,373 — To characterize the SARS-CoV-2 spike protein interaction with lectin receptors, we have expressed recombinant SARS-CoV-2 spike prefusion trimer using 293F freestyle expression system. Given the nanomolar high affinity of the spike protein binding to human ACE2, the entry receptor for SARS-CoV-2, an…
Jonathan W Yewdell · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $23,208 — We have generated Sleeping Beauty transposase vectors that drive expression of the SARS-CoV-2 receptor ACE2 and or protease TMPRSS2 in host cells and use these vectors to create permanent transfected lines of A549, 293FT, and BHK-21 cells. We have generated a recombinant vesicular stomatitis virus t…
Bernard Moss · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $34,549 — We constructed a panel of recombinant MVAs that express unmodified or modified SARS-CoV-2 spike (S) protein. Intramuscular injection of mice with the rMVAs induced antibodies, which neutralized a pseudovirus in vitro and upon passive transfer protected hACE2 transgenic mice from lethal infection wit…
Alan Koretsky · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · 2021 · $1,445,351 — We have made substantial progress towards Aims 1-5, 7&8. Specifically: a) We have reproducibly fabricated 3 nm iron oxide nanoparticles independently in our own lab. These serve as good T1 MRI contrast agents and have strong T2 contrast properties as well. b) We have developed several camelid VHH a…
Peter D Kwong · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $2,127,279 — Based on our understanding of spike- or envelope-based mechanisms of humoral evasion, we are working to design envelope-based immunogens with these evading mechanisms disabled. Such modified immunogens with weakened defenses may elicit more broadly neutralizing antibodies. We have also devised prote…